All the resolutions proposed by the Board of Directors were adopted Paris and Boston, June 5, 2025 - 5:45 p.m. CEST - Mauna Kea Technologies...
Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025
read more
Search Results
Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification
Cellvizio® technology combined with AI outperforms human experts in pancreatic cyst risk stratification, a major breakthrough for patient...
Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress
Ongoing Strategic Negotiations Towards a Licensing Agreement Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers...
Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation
Paris and Boston, May 20, 2025 - 5:45 p.m. CEST - Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025
Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on the...
Publication of the 2024 Annual Financial Report
Paris and Boston, April 30, 2025 – 9:15 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications
Pancreatic cyst abstracts build on endorsement of Cellvizio® by Europe’s leading endoscopy society, ESGE, as a key tool for improving pancreatic...
Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update
Commercial activities remain strong, including CellTolerance® launch Recently approved safeguard proceeding yielding productive creditor and...
Mauna Kea Technologies announces entrance into exclusive negotiations for a licensing agreement for Cellvizio® in an important therapeutic area with a major industry player
The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard...
Mauna Kea Technologies announces the opening of a safeguard proceeding to restructure its financial liabilities
The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The...
Cellvizio® Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis
ESGE, Europe’s leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step...
Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers
Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx,...